
electroCore EBITDA | ECOR
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA electroCore
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12.7 M | -11.4 M | -18.3 M | -22.3 M | -19.7 M | -24.3 M | -43.8 M | -54.5 M | -25.6 M | -15 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -11.4 M | -54.5 M | -24.8 M |
Quarterly EBITDA electroCore
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.56 M | -2.77 M | -5.3 M | -2.83 M | -2.77 M | -3.38 M | -3.67 M | -2.9 M | -2.47 M | -2.39 M | -3.64 M | -3.73 M | -3.84 M | -4.67 M | -6.08 M | -5.77 M | -5.4 M | -5.68 M | -5.48 M | -5.38 M | -3.89 M | -5.11 M | -5.29 M | -6.21 M | -4.25 M | -5.9 M | -7.99 M | -8.58 M | -10.9 M | -12.4 M | -14.2 M | -15.7 M | -13.5 M | -16.2 M | -9.09 M | -7.48 M | -5.98 M | -7.42 M | -4.74 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.56 M | -16.2 M | -6.27 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical instruments industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
BioLife Solutions
BLFS
|
-14.3 M | $ 38.61 | 3.51 % | $ 1.84 B | ||
|
Utah Medical Products
UTMD
|
12.2 M | $ 70.46 | -0.7 % | $ 228 M | ||
|
West Pharmaceutical Services
WST
|
756 M | $ 389.88 | -1.72 % | $ 28.2 B | ||
|
Baxter International
BAX
|
673 M | $ 25.39 | -0.02 % | $ 13 B | ||
|
Glaukos Corporation
GKOS
|
-162 M | $ 236.75 | -0.63 % | $ 13.5 B | ||
|
Atrion Corporation
ATRI
|
37.7 K | - | - | $ 810 M | ||
|
Milestone Scientific
MLSS
|
-5.62 M | $ 0.24 | -0.83 % | $ 19.7 M | ||
|
Alcon
ALC
|
1.36 B | $ 74.29 | -0.32 % | $ 36.6 B | ||
|
AtriCure
ATRC
|
2.64 M | $ 55.37 | 2.33 % | $ 2.64 B | ||
|
NeuroMetrix
NURO
|
-8.69 M | - | 5.05 % | $ 9.02 M | ||
|
Becton, Dickinson and Company
BDX
|
5.04 B | $ 212.18 | -0.26 % | $ 61 B | ||
|
AngioDynamics
ANGO
|
-17 M | $ 10.8 | 0.37 % | $ 448 M | ||
|
The Cooper Companies
COO
|
1.06 B | $ 58.8 | -2.54 % | $ 11.7 B | ||
|
Intuitive Surgical
ISRG
|
3.55 B | $ 400.35 | -1.69 % | $ 143 B | ||
|
Repro Med Systems
KRMD
|
-2.16 M | $ 3.19 | -7.41 % | $ 147 M | ||
|
InfuSystem Holdings
INFU
|
25.2 M | $ 14.39 | 2.35 % | $ 297 M | ||
|
OraSure Technologies
OSUR
|
-61.8 M | $ 3.48 | -3.6 % | $ 256 M | ||
|
iRhythm Technologies
IRTC
|
-36.7 M | $ 94.92 | 0.72 % | $ 3.04 B | ||
|
ResMed
RMD
|
2.09 B | $ 235.13 | -0.78 % | $ 34.2 B | ||
|
Harvard Bioscience
HBIO
|
-46.8 M | $ 8.62 | -0.69 % | $ 383 M | ||
|
CRH Medical Corporation
CRHM
|
33.9 M | - | - | $ 282 M | ||
|
Retractable Technologies
RVP
|
-13.4 M | $ 0.56 | -6.53 % | $ 16.8 M | ||
|
Microbot Medical
MBOT
|
-14.7 M | $ 0.68 | -8.79 % | $ 31.1 M | ||
|
Haemonetics Corporation
HAE
|
268 M | $ 119.94 | -0.3 % | $ 5.66 B | ||
|
Cantel Medical Corp.
CMD
|
123 M | - | -1.18 % | $ 3.4 B | ||
|
STERIS plc
STE
|
1.59 B | $ 255.68 | 0.31 % | $ 25.1 B | ||
|
ICU Medical
ICUI
|
244 M | $ 172.0 | -2.14 % | $ 4.24 B | ||
|
Merit Medical Systems
MMSI
|
308 M | $ 84.35 | -0.07 % | $ 4.99 B | ||
|
Nephros
NEPH
|
1.29 M | $ 2.72 | -4.26 % | $ 28.9 M | ||
|
Pro-Dex
PDEX
|
14.4 M | $ 62.2 | -2.03 % | $ 201 B | ||
|
Envista Holdings Corporation
NVST
|
332 M | $ 22.85 | -1.63 % | $ 3.84 B | ||
|
LeMaitre Vascular
LMAT
|
78.3 M | $ 73.73 | -1.52 % | $ 1.67 B | ||
|
Pulse Biosciences
PLSE
|
-76.5 M | $ 45.42 | 2.27 % | $ 3.06 B | ||
|
Repligen Corporation
RGEN
|
134 M | $ 163.68 | -3.88 % | $ 9.2 B | ||
|
Luminex Corporation
LMNX
|
72.9 M | - | - | $ 1.75 B | ||
|
STAAR Surgical Company
STAA
|
-83.4 M | $ 24.2 | -3.32 % | $ 1.2 B | ||
|
Akers Biosciences, Inc.
AKER
|
-12.3 M | - | -9.52 % | $ 20.6 M | ||
|
Teleflex Incorporated
TFX
|
192 M | $ 161.56 | -1.16 % | $ 7.21 B | ||
|
Antares Pharma, Inc.
ATRS
|
16.2 M | - | - | $ 955 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
518 M | - | -0.05 % | $ 10.3 B | ||
|
Varian Medical Systems, Inc.
VAR
|
60 M | - | -0.02 % | $ 16.3 B | ||
|
DENTSPLY SIRONA
XRAY
|
-70 M | $ 8.27 | -2.65 % | $ 1.65 B | ||
|
Ekso Bionics Holdings
EKSO
|
22.8 M | - | - | $ 28.6 M | ||
|
Isoray
ISR
|
-110 M | - | 0.03 % | $ 108 M | ||
|
Masimo Corporation
MASI
|
349 M | - | - | $ 9.59 B | ||
|
Stereotaxis
STXS
|
-21.5 M | $ 0.95 | -6.44 % | $ 86.4 M | ||
|
Predictive Oncology
POAI
|
-181 M | - | - | $ 31.1 M |